Temozolomide

For research use only. Not for use in humans.

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Temozolomide发表文献45篇:

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Ce41QPDhiaB?= MXzJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= M3XGRVI2QTZyMkiy
KellyCis83 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHjOFghcA>? M2\ZPWlEPTB;MkWxMlAx6oDLwsJihKkyPS55NTFOwG0> MoH6NlU6PjB{OEK=
SK-N-AS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq4OFghcA>? MnzYTWM2OD1{MkeuO|DjiIoEsfMAjVIzNjF3IN88US=> M3LKR|I2QTZyMkiy
SK-N-ASCis24 NF7TdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX60PEBp MWjJR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> MWCyOVk3ODJ6Mh?=
CHP-212 NUnBV5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK0PEBp MVPJR|UxRTdwOUhihKnDueLCiUCuOlkh|ryP NEnuSm4zPTl4MEK4Ni=>
CHP-212Cis100 NH\RUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHs[VY1QCCq MoK4TWM2OD17LkW15qCKyrIkgJmwMlg5KM7:TR?= MVyyOVk3ODJ6Mh?=
U87  Ml[ySpVv[3Srb36gRZN{[Xl? NU\1T|E2OTByIN88US=> MUeyOE04OiCq NV\qWmMxcW6mdXPld{BF[1JzIHX4dJJme3Orb36= NHTJeG8zPThyOEi2PC=>
LN229 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMVUxKM7:TR?= M2nJXWlEPTB;MU[g{txO MnXnNlU4PTB{N{O=
TR-LN229 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L0fVAuPTBizszN NVP0TZRyUUN3ME23O{DPxE1? NHLGeZozPTd3MEK3Ny=>
U87  M1HkZ2Fxd3C2b4Ppd{BCe3OjeR?= MlPaNQKBmzJyMPMAjeK2VQ>? NXrqdYRiOjRiaB?= MlXZ[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM> NEL6bo0zPTZ6MU[2PC=>
U251MG M2KzbGFxd3C2b4Ppd{BCe3OjeR?= NEXL[WIyODEEoN88US=> M2T6WFQ5KGh? NYS5cGhTWEKV NFftRlBqdmS3Y3XzJIFxd3C2b4Ppdy=> NVLYZ3VYOjV4OEC0OlQ>
U87MG NEfUUVFCeG:ydH;zbZMhSXO|YYm= NFH5RWoyODEEoN88US=> MkjuOFghcA>? NH3DVmpRSlN? M1XKVIlv\HWlZYOgZZBweHSxc3nz Mk\XNlU3QDB2NkS=
U87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhWYQ2OC1|NUCg{txO M2rnN|Q5yqCqwrC= MWfpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> Mn\ENlU2PTR{MkO=
U118  Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\nWZk2OC1|NUCg{txO M4L1cFQ5yqCqwrC= NETCdm1qdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MV:yOVU2PDJ{Mx?=
U87 NU\HSZVHTnWwY4Tpc44hSXO|YYm= MXqyOVAwOzVyIN88US=> MYO0POKhcMLi MX7lcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> NGflWWwzPTV3NEKyNy=>
U118  M1mxdmZ2dmO2aX;uJGF{e2G7 MVSyOVAwOzVyIN88US=> MVG0POKhcMLi NGPWNGFmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NGH2PWYzPTV3NEKyNy=>
U87 NH7US5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T1R|I2OC9|NUCg{txO MnnmOFjDqGkEoB?= NWLtUlRCcW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?= MnnLNlU2PTR{MkO=
A375 NIO0bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3O|Q5yqCqwrC= NYLy[4JSUUN3ME2yOlUh|ryP NFzNOlkzPTV{NEW1Ni=>
A2058 NY\XUW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjnOFjDqGkEoB?= MnvDTWM2OD1zMjFOwG0> NUDhPYE{OjV3MkS1OVI>
M238 M2TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO0POKhcMLi M4X5fGlEPTB;NECg{txO NW\BUGpXOjV3MkS1OVI>
M249 NWXvb4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37tN|Q5yqCqwrC= MUHJR|UxRTJ3NDFOwG0> MVSyOVUzPDV3Mh?=
M21 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jic|Q5yqCqwrC= MX\JR|UxRTJ{MTFOwG0> NULufYo2OjV3MkS1OVI>
U251 NEPJRmZEgXSxdH;4bZR6KEG|c3H5 M2DxN|IxKM7:TdMg NVOyT3p6PDkEoHlCpC=> NWPXWogyemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> Ml;kNlU1OzR|OEG=
LN229 MmrTR5l1d3SxeHn0fUBCe3OjeR?= M4q4UlIxKM7:TdMg NILXcow1QMLiaNMg MojvdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= MXeyOVQ{PDN6MR?=
U373MG-LUC NIjyeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NkBp NWDCeZZYUUN3ME62NFAh|ryP Mo[2NlU1OzF7NUO=
U87  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG0eoM1OjVvMkCwJO69VQ>? NGm0cYU1QMLiaNMg NImxNWdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2HpN|I2PDByN{S1
U251 NHXjdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqyOU0zODBizszN MlPLOFjDqGkEoB?= MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYSyOVQxODd2NR?=
U251 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNFAuPDByIN88US=> M{S0OFczNzl4IHi= M17Yd5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MnzyNlU{PzV{N{G=
U373 M{\LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxNFAuPDByIN88US=> MYS3Nk86PiCq M3v3[5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MkDpNlU{PzV{N{G=
U343 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\TW4cyODBvNECwJO69VQ>? NH3LSpo4Oi97NjDo NGPOR251cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MmPxNlU{PzV{N{G=
U87MG-luc2 M3jBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qwNlExOC12MECg{txO NIXqT|g4Oi97NjDo Moi2eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M{X2V|I2Ozd3Mkex
U87 MorOSpVv[3Srb36gRZN{[Xl? NFvHbmczODBizszN M4L3WVQ5KGh? MVnpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v MkDSNlU{Ozd5MkG=
U251 MXjGeY5kfGmxbjDBd5NigQ>? MX2yNFAh|ryP M2f6e|Q5KGh? NYHyW5Q1cW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NYXUR2ZOOjV|M{e3NlE>
A172 M1;VPWZ2dmO2aX;uJGF{e2G7 NXziZVA5OjByIN88US=> M2jj[VQ5KGh? NGPQZ|dqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NUP0bpp2OjV|M{e3NlE>
U251 MnrVSpVv[3Srb36gRZN{[Xl? MoC3NlAxKM7:TR?= NFi5V5I1QCCq MlXsbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MlnjNlU{Ozd5MkG=
A172 MYHGeY5kfGmxbjDBd5NigQ>? NGHB[GEzODBizszN MUW0PEBp MUjpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz MWmyOVM{Pzd{MR?=
U87 M2fKdWZ2dmO2aX;uJGF{e2G7 NX\OT|IzOjByIN88US=> M{GyT|I1Nzd{L{GyNEBp NUDSfpgycW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MV2yOVM{Pzd{MR?=
U251 M{O5bGZ2dmO2aX;uJGF{e2G7 Mn7YNlAxKM7:TR?= NETyWmszPC95Mj:xNlAhcA>? MUjpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NGriVFczPTN|N{eyNS=>
A172 NVfwZlhTTnWwY4Tpc44hSXO|YYm= Mke0NlAxKM7:TR?= MV[yOE84Oi9zMkCgbC=> M3fTU4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MoO3NlU{Ozd5MkG=
SNB19V NIDoeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq3JIQ> M3L6eWROW09? NUXsdYdMT0l3ME2zOU44yrFzMjFOwG0> M2nEPVI2Ojd5NESx
SNB19M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqxO{Bl M1HzRWROW09? MV3HTVUxRTR4OT65xtE5QCEQvF2= NH\6VY8zPTJ5N{S0NS=>
SNB19VR MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n4TVch\A>? M1fmRmROW09? NG\LRWFIUTVyPUK4NE4zyrFzODFOwG0> MXeyOVI4PzR2MR?=
U373V MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnzO{Bl MXPEUXNQ NH2zWWNIUTVyPU[4MlDDuTN{IN88US=> M37sOVI2Ojd5NESx
U373M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL0TXc4KGR? NXqxdoRDTE2VTx?= Ml34S2k2OD1|NkiuO:KyQDZizszN MmTCNlUzPzd2NEG=
U373VR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P0[|ch\A>? M2P1b2ROW09? NIrVbmFIUTVyPUK4PE45yrF|MzFOwG0> M{ntcFI2Ojd5NESx
U87MG M3jEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf2Soc4PyCm MkfUSG1UVw>? NV76VWZZT0l3ME2zPE4{yrF{MDFOwG0> MXiyOVI4PzR2MR?=
HCT116 NG\LNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3JIQ> Mk\QSG1UVw>? NV;yVodTT0l3ME21O|kvQcLzM{Kg{txO MUiyOVI4PzR2MR?=
DLD1 NH[1OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRXVch\A>? MYnEUXNQ MXrHTVUxRTVyMT60xtE6OyEQvF2= NIDWSm8zPTJ5N{S0NS=>
MRC5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:zUVVLPyCm MXvEUXNQ MUPHTVUxRTR2OT60xtE5KM7:TR?= NIHTdlczPTJ5N{S0NS=>
SNB19V  MXnGeY5kfGmxbjDBd5NigQ>? M4PXTFExOCEQvF5CpHROYg>? M1vMO|AuPzJiaB?= M{XIXolv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp NGLrcoYzPTJ5N{S0NS=>
T98G  NGe3TVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjScVYyPS9zMD:xOUDPxE1? NEXtUoczPMLiaB?= NYTvSoprcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> NEHxc2IzPTJ4Mkm2NS=>
U251  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe1M|ExNzF3IN88US=> MW[yOOKhcA>? M3G0b4lv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU MXGyOVI3Ojl4MR?=
T98G  NXLZbmVRTnWwY4Tpc44hSXO|YYm= Mmq3NVUh|ryP MmTXNlTDqGh? NWnhfmRxcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz M{fxSFI2OjZ{OU[x
U251  NUjCUYc6TnWwY4Tpc44hSXO|YYm= NEjQOHAyPSEQvF2= M3q3Z|I1yqCq NYfkZZgzcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz NV;sbVlQOjV{NkK5OlE>
U-87 MG NEDQ[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp M2faS2lEPTB;MD65N{BuVcLi Ml3rNlUzPDV|M{K=
U-118 MG NV\BN3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PxTlczKGh? M2LMN2lEPTB;MT6wOUBuVcLi Mly3NlUzPDV|M{K=
U87 M2PQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWwRWhSOjRiaB?= NIHJRXRKSzVyPUK2NE4{PCEQvF5CpC=> Mor4NlUyPzN{M{O=
U87 GSLCs MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPvXWczPCCq NFjoeXNKSzVyPUe2Ok4yOSEQvF5CpC=> MWKyOVE4OzJ|Mx?=
U87MG NYW3W3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzIO|IhcA>? MkT3TWM2OD1zNT62NlUh|ryPwrC= M3\KXVI2ODVyOUG1
U251 M1jyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPvNVAxNTRyMDFOwG0> NXPmN|N3PDhiaB?= M3jRR2ROW09? NH7WZW1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV65SHNvOjR4MkO3N|Y>
U87 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy4XJllOTByLUSwNEDPxE1? MmSxOFghcA>? NGP1WopFVVOR M1fjUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4LSO|I1PjJ|N{O2
MDA-MB-231-br M1;Lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMVExKM7:TR?= NVK0ZnlVPDhiaB?= MnvBSG1UVw>? MlS4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVG5OFJYOjR4MkO3N|Y>
HCC-1937 NIHYTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzcG5rOC1|MECg{txO MlPBOFghcA>? NV\2cJJUTE2VTx?= Mmj2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlXENlQ3OjN5M{[=
MDA-MB-231 NGmyZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOwMVQxKM7:TR?= MVq0PEBp MXfEUXNQ NUXlWFA{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3fkT|I1PjJ|N{O2
MDA-MB-468 NVrhNpNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6NE02ODBizszN NWi2dpBoPDhiaB?= MUTEUXNQ MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkjHNlQ3OjN5M{[=
T47D M2TmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMVExOCEQvF2= MUG0PEBp NYPQ[npYTE2VTx?= NWjVbFhDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXyyOFYzOzd|Nh?=
MCF7 NELPR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rFflAuOTByMDFOwG0> MWC0PEBp NFzWcXNFVVOR MmPpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXKyOFYzOzd|Nh?=
Hs683 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHYWHhYOC1zMECwJO69VQ>? MYe5OkBp NF\le2hKSzVyPUGyPE46KM7:TR?= M4\M[VI1PDl3OUC3
U87 NIjmNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvp[2kxNTFyMECg{txO NUflUHN4QTZiaB?= MWHJR|UxRTF6LkS1JO69VQ>? NGLRVnIzPDR7NUmwOy=>
LNZ308 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2fIoxNTFyMECg{txO NE\Ve3c6PiCq NYnKfW5oUUN3ME2zNlYvPyEQvF2= M{e5eFI1PDl3OUC3
U87 M1:4emFxd3C2b4Ppd{BCe3OjeR?= M2fZ[|ExOCEQvF2= NYPnVWN6PDhiaB?= MlO1SG1UVw>? NVzB[o9ucW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NGC5VWYzPDR6MUW4Oi=>
U251  NXixbVJWSXCxcITvd4l{KEG|c3H5 NUnjNFFLOTByIN88US=> MmLsOFghcA>? NFS2[|VFVVOR MV;pcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 MUmyOFQ5OTV6Nh?=
U251 M2HvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETE[pIzPCCq M4r1PGlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN NXj0eFFXOjR|Mk[5OVQ>
U251 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf6NXhqPDhiaB?= MWDJR|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?= NEfqRYQzPDN{Nkm1OC=>
U251 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojJO|IhcA>? MVjJR|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?= MUeyOFMzPjl3NB?=
U251 M3XBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PiUFk3KGh? M33sZ2lEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN MUSyOFMzPjl3NB?=
T98G NWG3eGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoNE04PTBizszN MluzO|IwQTZiaB?= MYDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHX3UnkzPDN{NEC4NC=>
U251-MG NUPZbVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPydZB3OC16MECg{txO NHLmcIM4OiCq M2rRUolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MonwNlQxQTN4M{C=
D54-MG NEPZdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOzNGJ{OC16MECg{txO NHnnT|Y4OiCq MnTXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGPwUm8zPDB7M{[zNC=>
SHG-44 NXH5WWtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTWNVAuOjByIN88US=> MXW5OkBp M4XYUWlEPTB;OT63N{DDuSB{LkGyJO69VQ>? MnfONlQxPjV3Nkm=
U373  MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\BdJgyOC1{MECg{txO NVjVSph7QTZiaB?= NV7PVZNHUUN3ME2xNE4yOyEEsTCxMlAzKM7:TR?= NYj2WJJGOjRyNkW1Olk>
HT-29  MnTBSpVv[3Srb36gRZN{[Xl? M2XPeFUxOCEQvF2= MWmyOE81QCCq Mo\6[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NHroZYozPDB|OEC2PC=>
PC-3  NFnlWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVI2KM7:TR?= NYW4PGV1PDhiaB?= MXzpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NWnyUnY1OjN5NE[5N|Q>
PC-3  MYrBdI9xfG:|aYOgRZN{[Xl? NV7xS5VmOjVizszN NXvHcFRSPDhiaB?= NEDLU2VqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> MYWyN|c1Pjl|NB?=
T98G NHjkXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnGR21pPTBvNECwJO69VQ>? MWexOFQhcA>? NFm5W4RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUSy[2ZCOjN5MUW0PVk>
U87-MG M1r0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWro[mxvOTByINM1US=> MnXUO|IhcA>? NUnBWWp2cW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MXOyN|Y6Pjd6OB?=
U251-MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjkN5oyODBiwsXN MmDyO|IhcA>? Mm\qbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? M4Kz[FI{Pjl4N{i4
LNT-229 NXH4TWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUezMVExOCEQvF2= NIf2SVczPCCq MULpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVXsXGhGOjN4Nke2N|I>
T98G NIXZVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDvflAyOC15MECg{txO M162eVI1KGh? NFnabGpqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnT1NlM3Pjd4M{K=
U87  NIrqS2JHfW6ldHnvckBCe3OjeR?= MX6xNFAhyrWP MW[zJIg> MlXJ[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> MlnHNlM3Pjd2Nkm=
HCT116 NHnjZppHfW6ldHnvckBCe3OjeR?= M3yxTFExOCEEtV2= NVfBRlR4OyCq M{\OUIlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w M{Xm[|I{PjZ5NE[5
HCT3-6 NWTPbJhiTnWwY4Tpc44hSXO|YYm= MUSxNFAhyrWP NWDwOWgxOyCq NXXxZnN6cW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= MlzrNlM3Pjd2Nkm=
U-87  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfQNE01OCEQvF2= M4LLTFEzKGR? M4PD[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkLUNlM3PDV5Mkm=
U-87  M3PLb2Fxd3C2b4Ppd{BCe3OjeR?= NETEcnMxNTRyIN88US=> M2fWU|MwPiCm MXXpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NWrIV|BwOjN4NEW3Nlk>
U-87  NXPub|BGTnWwY4Tpc44hSXO|YYm= M3nRXVAuPDBizszN MkTJN{83KGR? NH7XRndqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M3H5ZVI{PjR3N{K5
GB-SCC010 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0JIQ> NICzZ3ZKSzVyPUKyOkDPxE1? Mmr6NlM3OTJ5NUW=
GB-SCC026 Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4VphHPCCm MWLJR|UxRTV|LkGg{txO MVuyN|YyOjd3NR?=
GB-SCC028 M{PkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy0JIQ> NWrvTpBsUUN3ME2xOlch|ryP NFXCXnczOzZzMke1OS=>
U87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjrTmNKPCCm NWrYbW5OUUN3ME20OU4zKM7:TR?= MmTJNlM3OTJ5NUW=
U87 stem cell NETMVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG4VIc4PCCm Ml20TWM2OD14Nj63JO69VQ>? NX\TU21zOjN4MUK3OVU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
储存条件 粉状
溶于溶剂
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) November 1 2019 Early Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2
NCT03709680 Recruiting Drug: Palbociclib|Drug: Temozolomide|Drug: Irinotecan Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma Pfizer May 24 2019 Phase 1
NCT03832621 Recruiting Drug: Temozolomide|Drug: Nivolumab|Drug: Ipilimumab Metastatic Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano March 25 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID